ir.tgtherapeutics.comInvestor Relations | TG Therapeutics, Inc.
ir.tgtherapeutics.com Profile
ir.tgtherapeutics.com
Maindomain:tgtherapeutics.com
Title:Investor Relations | TG Therapeutics, Inc.
Description：The Investor Relations website contains information about TG Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.
Discover ir.tgtherapeutics.com website stats, rating, details and status online.Use our online tools to find owner and admin contact info. Find out where is server located.Read and write reviews or vote to improve it ranking. Check alliedvsaxis duplicates with related css, domain relations, most used words, social networks references. Go to regular site
ir.tgtherapeutics.com Information
| Website / Domain: | ir.tgtherapeutics.com |
| HomePage size: | 54.516 KB |
| Page Load Time: | 0.076418 Seconds |
| Website IP Address: | 172.231.14.194 |
| Isp Server: | Akamai Technologies Inc. |
ir.tgtherapeutics.com Ip Information
| Ip Country: | United States |
| City Name: | San Francisco |
| Latitude: | 37.774929046631 |
| Longitude: | -122.41941833496 |
ir.tgtherapeutics.com Keywords accounting
| Keyword | Count |
|---|
ir.tgtherapeutics.com Httpheader
| Accept-Ranges: bytes |
| Content-Encoding: gzip |
| Content-Language: en |
| Content-Type: text/html; charset=UTF-8 |
| device: desktop |
| ETag: "1589754523" |
| Expect-CT: max-age=0, report-uri="/report-expect-ct-violation" |
| Feature-Policy: "accelerometer none;ambient-light-sensor none;autoplay self;camera none;encrypted-media none;fullscreen self;geolocation self;gyroscope none;magnetometer none;microphone none;midi none;payment none;picture-in-picture none;speaker self;sync-xhr self;usb none;vibrate none;vr none", From-Origin: same |
| Last-Modified: Sun, 17 May 2020 22:28:43 GMT |
| Link: http://ir.tgtherapeutics.com/; rel="shortlink", http://ir.tgtherapeutics.com/; rel="canonical", http://ir.tgtherapeutics.com/investor-relations; rel="alternate"; hreflang="en", http://ir.tgtherapeutics.com/investor-relations; rel="revision" |
| Referrer-Policy: no-referrer-when-downgrade |
| Server: nginx |
| X-Age: 0 |
| X-Content-Type-Options: nosniff |
| X-Drupal-Dynamic-Cache: UNCACHEABLE |
| X-Frame-Options: SAMEORIGIN |
| X-Generator: Drupal 8 (https://www.drupal.org) |
| X-Request-ID: v-c3fc25a8-988d-11ea-9974-cf046180a01e |
| X-UA-Compatible: IE=edge |
| X-XSS-Protection: 1; mode=block |
| Content-Length: 11835 |
| X-EdgeConnect-MidMile-RTT: 107, 107 |
| X-EdgeConnect-Origin-MEX-Latency: 763, 763 |
| Cache-Control: public, max-age=0, s-maxage=1800 |
| Expires: Sun, 17 May 2020 22:28:44 GMT |
| Date: Sun, 17 May 2020 22:28:44 GMT |
| Connection: keep-alive |
| Vary: Accept-Encoding |
| Set-Cookie: SimpleSAMLSessionID=30c4df2938f8cc6008c7c315586fc721; path=/; secure; HttpOnly, DrupalVisitorMobile=0; path=/; Secure; HttpOnly |
ir.tgtherapeutics.com Meta Info
| charset="utf-8"/ |
| content="Investor Relations | TG Therapeutics, Inc." name="title"/ |
| content="TG Therapeutics, Inc." property="og:site_name"/ |
| content="website" property="og:type"/ |
| content="The Investor Relations website contains information about TG Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts." name="description"/ |
| content="http://ir.tgtherapeutics.com/investor-relations" property="og:url"/ |
| content="Investor Relations | TG Therapeutics, Inc." property="og:title"/ |
| content="no-referrer" name="referrer"/ |
| content="The Investor Relations website contains information about TG Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts." property="og:description"/ |
| content="Drupal 8 (https://www.drupal.org)" name="Generator"/ |
| content="width" name="MobileOptimized"/ |
| content="true" name="HandheldFriendly"/ |
| content="width=device-width, initial-scale=1.0" name="viewport"/ |
172.231.14.194 Domains
| Domain | WebSite Title |
|---|
ir.tgtherapeutics.com Similar Website
| Domain | WebSite Title |
|---|---|
| Investor Relations TG Therapeutics Inc | |
| Investor Relations | TG Therapeutics, Inc. | |
| Investor Relations - Revance Therapeutics, Inc. | |
| Investor Overview | Mateon Therapeutics | |
| INVESTOR OVERVIEW Insys Therapeutics Inc | |
| Investor Overview | Mateon Therapeutics | |
| Investor Relations :: BioXcel Therapeutics, Inc. (BTAI) | |
| Nelnet Inc - Investor Resources - Investor Services Program | |
| Exantas Investor Relations - Investor Overview | |
| Winnebago Investor Relations Investor Home | |
| Spark Therapeutics | |
| About Us | Nektar Therapeutics | |
| United Therapeutics | |
| Investors | PTC Therapeutics, Inc. | |
| Careers | Ebb Therapeutics |
ir.tgtherapeutics.com Traffic Sources Chart
ir.tgtherapeutics.com Alexa Rank History Chart
ir.tgtherapeutics.com Html To Plain Text
Skip to main navigation About Us Our Story Message From CEO Our Leadership Our Board Our Science Our Approach Therapeutic Focus Work with Us Our Pipeline Overview UBLITUXIMAB UMBRALISIB TG-1501 TG-1701 TG-1801 Our Publications Our Trials Overview Pivotal Trials Investors & Media Press Releases Stock Information Historic Stock Lookup SEC Filings & Financials Quarterly Results Annual Reports SEC Filings Events IR & Media Contact Management Team Corporate Governance FAQs CAREERS CONTACT US Twitter Close About Us Our Story Message From CEO Our Leadership Our Board Our Science Our Approach Therapeutic Focus Work with Us Our Pipeline Overview UBLITUXIMAB UMBRALISIB TG-1501 TG-1701 TG-1801 Our Publications Our Trials Overview Pivotal Trials Investors & Media Press Releases Stock Information Historic Stock Lookup SEC Filings & Financials Quarterly Results Annual Reports SEC Filings Events IR & Media Contact Management Team Corporate Governance FAQs Investors & Media Investor Relations Investor Relations TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies and autoimmune diseases. Ublituximab (TG-1101) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing umbralisib (TGR-1202), an oral, once-daily inhibitor of PI3K-delta. Umbralisib uniquely inhibits CK1-epsilon, which may allow it to overcome certain tolerability issues associated with first generation PI3K-delta inhibitors. Both ublituximab and umbralisib, or the combination of which is referred to as "U2", are in Phase 3 clinical development for patients with hematologic malignancies, with ublituximab also in Phase 3 clinical development for Multiple Sclerosis. Additionally, the Company has recently brought its anti-PD-L1 monoclonal antibody, TG-1501, its covalently-bound Bruton’s Tyrosine Kinase (BTK) inhibitor, TG-1701, as well as its anti-CD47/CD19 bispecific antibody, TG-1801, into Phase 1 development. TG Therapeutics is headquartered in New York City. Currently, TG Therapeutics uses the following social media channels: - Twitter November 2019 Corporate Presentation Quote Chart NASDAQ: TGTX Change Volume 52 Week High 52 Week Low May 17, 2020 6:28 PM EDT Copyright West LLC. Minimum 15 minutes delayed. Recent Releases May 15, 2020 TG Therapeutics Announces Preclinical Data Presentation at the Upcoming American Association for Cancer Research Annual Meeting May 14, 2020 TG Therapeutics Announces Pricing of Upsized Public Offering of Common Stock View all Email Alerts RSS News Feeds Print Page Share facebook linkedin twitter Search 2 Gansevoort Street, 9th Floor New York, NY 10014 Email Us (212) 554-4484 TG Therapeutics © . All rights reserved. Join us Contact Us Privacy Policy Terms of Use...
ir.tgtherapeutics.com Whois
"domain_name": "TGTHERAPEUTICS.COM",
"registrar": "Network Solutions, LLC",
"whois_server": "whois.networksolutions.com",
"referral_url": null,
"updated_date": [
"2019-10-07 08:07:10",
"2019-10-07 08:16:02"
],
"creation_date": "2011-12-06 14:57:45",
"expiration_date": "2020-12-06 14:57:45",
"name_servers": [
"NS47.WORLDNIC.COM",
"NS48.WORLDNIC.COM"
],
"status": "clientTransferProhibited https://icann.org/epp#clientTransferProhibited",
"emails": [
"abuse@web.com",
"wy7uz2jm7bc@networksolutionsprivateregistration.com"
],
"dnssec": "unsigned",
"name": "PERFECT PRIVACY, LLC",
"org": null,
"address": "5335 Gate Parkway care of Network Solutions PO Box 459",
"city": "Jacksonville",
"state": "FL",
"zipcode": "32256",
"country": "US"